Last reviewed · How we verify
NCT06163222
Behavioural Interventions to Improve Equity in Outpatient Access
NA trial testing Additional message with behavioural science-informed content and associated web pages in Behavioural Science Interventions to Improve Health Equity in 13,389 participants. Completed in 20 November 2024.
20 November 2024
Quick facts
| Lead sponsor | Imperial College London |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | health services research |
| Enrollment | 13,389 |
| Start date | 8 January 2024 |
| Primary completion | 20 November 2024 |
| Estimated completion | 20 November 2024 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Additional message with behavioural science-informed content and associated web pages
- Usual communication strategy
Conditions studied
- Behavioural Science Interventions to Improve Health Equity — all drugs for Behavioural Science Interventions to Improve Health Equity →
Sponsor
Imperial College London
Who can join
18 and older, any sex, with Behavioural Science Interventions to Improve Health Equity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to improve health equity within outpatient service access. This is through design and behavioural science-informed interventions that aim to improve rates of first outpatient appointment attendance. Health equity refers to the avoidable and unfair differences in health access, outcomes and experience between groups or populations. Outpatient services are those appointments where advice from a specialised medical professional is provided to a patient in a clinic setting. This clinical trial aims to test different ways of supporting people to attend their first outpatient appointments at five clinical specialties (ophthalmology, gastroenterology, colorectal surgery, cardiology and plastic surgery) at Imperial College Healthcare NHS Trust (ICHT). It is specifically focused on improving attendance for people who are most likely to miss their appointment based on ICHT data, which includes people from minority ethnic backgrounds and people living in the most deprived postcodes. The main question this clinical trial aims to answer is: • Do behavioural science-informed message interventions improve rates of first outpatient appointment attendance in patients facing inequity of access based on ethnicity and deprivation? The secondary questions this clinical trial aims to answer include: * Do behavioural science-informed message interventions improve rates of first outpatient appointment attendance across all patient groups? * Do behavioural science-informed message interventions increase the number of patients who "self-cancel" their appointment if they need to? * In which patient groups did the message interventions have most impact, e.g., a certain age range? * Which factors were associated with improved outpatient attendance rates specifically in participants from minority ethnic groups or living in area with highest level of deprivation? * What was the overall outcome of all first outpatient appointments included in the clinical trial? * What was the overall successful message delivery rate for the messages sent as part of the study? Were there particular participant groups that were more likely to have an undelivered message? * What was the overall outcome of appointment attendance for people who received a text message intervention compared with receiving a text message and/or email intervention? * How well did participants engage with the message interventions e.g. did they click the link provided in the message?
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06163222
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Imperial College London trials
Trials by the same sponsor.
- NCT06035861 — Endothelial Cell Activation and Total Pulmonary Resistance in PAH · NA · not yet recruiting
- NCT07397455 — Development of a Controlled Human Infection Model for Assessment of SARS-CoV-2 Omicron Subvariants · Phase 1 · not yet recruiting
- NCT07422532 — A Multi-centre Trial to Assess the Efficacy and Safety of the Omnipod 5 System in People With Type 2 Diabetes Undergoing · NA · not yet recruiting
- NCT07389031 — Maralixibat for Intrahepatic Cholestasis of Pregnancy · Phase 2 · not yet recruiting
- NCT07358897 — Gender Affirming Hormone Therapy and Immune Function in Trans Individuals - The GIFT Study · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06163222 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Imperial College London
- Last refreshed: 9 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06163222.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing